Healthpoint today announced its acquisition of two cellbased technologies from Intercytex Limited along with the corresponding intellectual property (including patents), validated fibroblast and keratinocyte cell banks, and related production and testing equipment. Terms of the deal were not disclosed by Healthpoint.

The therapeutic candidates acquired include CYZACT™--human dermal fibroblasts delivered via a fibrin sheet and produced utilizing a streamlined manufacturing process as compared to similar products—and ICX-SKN--a combination of fibroblasts and fibrin matrix that are remodeled to produce a collagen matrix that allows the engineered tissue to remain intact in a hostile wound environment. The validated cell banks and equipment will be transferred to Healthpoint’s cell-based manufacturing facility in Lausanne, Switzerland, which is authorized by Swissmedic (the Swiss Regulatory Agency) for the production of both allogeneic (i.e., derived outside of patient’s own body) cell therapies and autologous (i.e., derived from patient’s own body) tissue products.

(FORT WORTH, TX) —HEALTHPOINT, Ltd. today announced that it has enrolled the first of a planned 235 subjects into a Phase II dose response study investigating an experimental, cell-based wound therapy ---HP802-247---intended for the treatment of venous leg ulcers. HP802-247 is a topical spray containing living keratinocytes and fibroblasts. The first patient was enrolled at The Center for Clinical Research near San Francisco, Calif., led by the site’s principal investigator, Alexander Reyzelman, DPM. The study is being conducted by 28 investigators in 18 states.

(Fort Worth, TX) --- H. Paul Dorman, Chairman and Chief Executive Officer of Fort Worth-based DFB Pharmaceuticals, Inc., has announced that Travis E. Baugh has joined HEALTHPOINT^®, Ltd., a DFB Pharmaceuticals company, as President and Chief Operating Officer.